HC Wainwright & Co. Initiates Coverage On Mural Oncology with Buy Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Mural Oncology with a Buy rating and set a price target of $18.
October 17, 2024 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Mural Oncology with a Buy rating and set a price target of $18, indicating positive expectations for the stock.
The initiation of coverage with a Buy rating and a specific price target of $18 by a reputable firm like HC Wainwright & Co. suggests a positive outlook for Mural Oncology. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100